Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 2—February 2015
Online Report

Melioidosis Diagnostic Workshop, 20131

Alex R. HoffmasterComments to Author , David AuCoin, Prasith Baccam, Henry C. Baggett, Rob Baird, Saithip Bhengsri, David D. Blaney, Paul J. Brett, Timothy J.G. Brooks, Katherine A. Brown, Narisara Chantratita, Allen C. Cheng, David A.B. Dance, Saskia Decuypere, Dawn Defenbaugh, Jay E. Gee, Raymond Houghton, Possawat Jorakate, Ganjana Lertmemongkolchai, Direk Limmathurotsakul, Toby L. Merlin, Chiranjay Mukhopadhyay, Robert Norton, Sharon J. Peacock, Dionne B. Rolim, Andrew J. Simpson, Ivo Steinmetz, Robyn A. Stoddard, Martha M. Stokes, David Sue, Apichai Tuanyok, Toni Whistler, Vanaporn Wuthiekanun, and Henry Walke
Author affiliations: US Centers for Disease Control and Prevention, Atlanta, Georgia, USA (A.R. Hoffmaster, D.D. Blaney, J.E. Gee, T.L. Merlin, R.A. Stoddard, D. Sue, H.T. Walke); University of Nevada School of Medicine, Reno, Nevada, USA (D. AuCoin); IEM, Research Triangle Park, North Carolina, USA (P. Baccam); Royal Darwin Hospital, Darwin, Northern Territory, Australia (R. Baird); US Centers for Disease Control and Prevention, Nonthaburi, Thailand (H.C. Baggett, S. Bhengsri, P. Jorakate, T. Whistler); University of South Alabama, Mobile, Alabama, USA (P.J. Brett); Public Health England, Salisbury, UK (T.J.G. Brooks, A.J. Simpson); University of Texas, Austin, Texas, USA (K.A. Brown); University of Cambridge, Cambridge, UK (K.A. Brown, S.J. Peacock); Mahidol University, Bangkok, Thailand (N. Chantratita, D. Limmathurotsakul, V. Wuthiekanun); Alfred Health, Monash University, Melbourne, Victoria, Australia (A. C. Cheng); Lao-Oxford-Mahosot Hospital–Wellcome Trust Research Unit, Vientiane, Laos, and University of Oxford, Oxford, UK (D.A.B. Dance); University of Western Australia, Perth, Western Australia, Australia (S. Decuypere); Defense Threat Reduction Agency, Fort Belvoir, Virginia, USA (D. Defenbaugh, M.M. Stokes); InBios International, Seattle, Washington, USA (R. Houghton); Khon Kaen University, Khon Kaen, Thailand (G. Lertmemogkolchai); Kasturba Medical College, Manipal, India (C. Mukhopadhyay); Townsville Hospital, Townsville, Queensland, Australia (R. Norton); Universidade de Fortaleza, Fortaleza, Brazil (D. B. Rolim); University of Greifswald, Greifswald, Germany (I. Steinmetz); University of Hawaii at Manoa, Honolulu, Hawaii, USA (A. Tuanyok)

Main Article

Figure

Diagnostic guidelines for clinicians and microbiologists in developed countries and resource-limited settings. 1The antimicrobial drug–susceptibility pattern can be useful for distinguishing Burkholderia pseudomallei (usually resistant to aminoglycosides and colistin or polymyxin but susceptible to amoxicillin/clavulanic acid) from other pathogenic species. However, isolates can occasionally be susceptible to aminoglycosides; susceptibility may vary by region (40). If disk diffusion is used, zon

Figure. Diagnostic guidelines for clinicians and microbiologists in developed countries and resource-limited settings. 1) The antimicrobial drug–susceptibility pattern can be useful for distinguishing Burkholderia pseudomallei (usually resistant to aminoglycosides and colistin or polymyxin but susceptible to amoxicillin/clavulanic acid) from other pathogenic species. However, isolates can occasionally be susceptible to aminoglycosides; susceptibility may vary by region (40). If disk diffusion is used, zone diameter interpretation may need to be modified from break points recommended for Enterobacteriaceae by the Clinical and Laboratory Standards Institute (73). 2) Not currently commercially available. API 20NE, bioMérieux, Craponne, France; VITEK, Becton, Dickinson, and Company, Franklin Lakes, NJ, USA.

Main Article

References
  1. Wiersinga  WJ, Currie  BJ, Peacock  SJ. Melioidosis. N Engl J Med. 2012;367:1035–44. DOIPubMedGoogle Scholar
  2. Ngauy  V, Lemeshev  Y, Sadkowski  L, Crawford  G. Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II. J Clin Microbiol. 2005;43:970–2. DOIPubMedGoogle Scholar
  3. Peacock  SJ, Schweizer  HP, Dance  DA, Smith  TL, Gee  JE, Wuthiekanun  V, Management of accidental laboratory exposure to Burkholderia pseudomallei and B. mallei. Emerg Infect Dis. 2008;14:e2. DOIPubMedGoogle Scholar
  4. John  TJ, Jesudason  MV, Lalitha  MK, Ganesh  A, Mohandas  V, Cherian  T, Melioidosis in India: the tip of the iceberg? Indian J Med Res. 1996;103:62–5 .PubMedGoogle Scholar
  5. Kibbler  CC, Roberts  CM, Ridgway  GL, Spiro  SG. Melioidosis in a patient from Bangladesh. Postgrad Med J. 1991;67:764–6. DOIPubMedGoogle Scholar
  6. Stewart  T, Engelthaler  DM, Blaney  DD, Tuanyok  A, Wangsness  E, Smith  TL, Epidemiology and investigation of melioidosis, southern Arizona. Emerg Infect Dis. 2011;17:1286–8. DOIPubMedGoogle Scholar
  7. Zehnder  AM, Hawkins  MG, Koski  MA, Lifland  B, Byrne  BA, Swanson  AA, Burkholderia pseudomallei isolates in 2 pet iguanas, California, USA. Emerg Infect Dis. 2014;20:304–6. DOIPubMedGoogle Scholar
  8. Wuthiekanun  V, Dance  DA, Wattanagoon  Y, Supputtamongkol  Y, Chaowagul  W, White  NJ. The use of selective media for the isolation of Pseudomonas pseudomallei in clinical practice. J Med Microbiol. 1990;33:121–6. DOIPubMedGoogle Scholar
  9. Wuthiekanun  V, Suputtamongkol  Y, Simpson  AJ, Kanaphun  P, White  NJ. Value of throat swab in diagnosis of melioidosis. J Clin Microbiol. 2001;39:3801–2. DOIPubMedGoogle Scholar
  10. Cheng  AC, Wuthiekanun  V, Limmathurosakul  D, Wongsuvan  G, Day  NP, Peacock  SJ. Role of selective and nonselective media for isolation of Burkholderia pseudomallei from throat swabs of patients with melioidosis. J Clin Microbiol. 2006;44:2316. DOIPubMedGoogle Scholar
  11. Peacock  SJ, Chieng  G, Cheng  AC, Dance  DA, Amornchai  P, Wongsuvan  G, Comparison of Ashdown’s medium, Burkholderia cepacia medium, and Burkholderia pseudomallei selective agar for clinical isolation of Burkholderia pseudomallei. J Clin Microbiol. 2005;43:5359–61 and. DOIPubMedGoogle Scholar
  12. Thorn  P, Krause  V, Boutlis  C, Currie  B. Melioidosis in the Top End. The Northern Territory Disease Control Bulletin. 2005;12:1–2 [cited 2014 Dec 4]. http://www.health.nt.gov.au/library/scripts/objectifyMedia.aspx?file=pdf/11/41.pdf&siteID=1&str_title=Bulletin+December+2005.pdf
  13. Limmathurotsakul  D, Wuthiekanun  V, Chierakul  W, Cheng  AC, Maharjan  B, Chaowagul  W, Role and significance of quantitative urine cultures in diagnosis of melioidosis. J Clin Microbiol. 2005;43:2274–6. DOIPubMedGoogle Scholar
  14. Centers for Disease Control and Prevention. Laboratory exposure to Burkholderia pseudomallei—Los Angeles, California, 2003. MMWR Morb Mortal Wkly Rep. 2004;53:988–90 .PubMedGoogle Scholar
  15. Pumpuang  A, Chantratita  N, Wikraiphat  C, Saiprom  N, Day  NP, Peacock  SJ, Survival of Burkholderia pseudomallei in distilled water for 16 years. Trans R Soc Trop Med Hyg. 2011;105:598–600. DOIPubMedGoogle Scholar
  16. Yabuuchi  E, Wang  L, Arakawa  M, Yano  I. Survival of Pseudomonas pseudomallei strains at 5 degrees C. Kansenshogaku Zasshi. 1993;67:331–5. DOIPubMedGoogle Scholar
  17. Larsen  E, Smith  JJ, Norton  R, Corkeron  M. Survival, sublethal injury, and recovery of environmental Burkholderia pseudomallei in soil subjected to desiccation. Appl Environ Microbiol. 2013;79:2424–7. DOIPubMedGoogle Scholar
  18. Holland  DJ, Wesley  A, Drinkovic  D, Currie  BJ. Cystic fibrosis and Burkholderia pseudomallei: an emerging problem? Clin Infect Dis. 2002;35:e138–40. DOIPubMedGoogle Scholar
  19. Wesley  A, Holland  D, Currie  B. Burkholderia pseudomallei in two siblings with cystic fibrosis and evidence of likely person to person transmission in the family setting. In: Proceedings of Fourth Australian and New Zealand Cystic Fibrosis Conference; 2001 Aug 23–25, Brisbane, Australia. p. 46.
  20. Price  EP, Sarovich  DS, Mayo  M, Tuanyok  A, Drees  KP, Kaestli  M, Within-host evolution of Burkholderia pseudomallei over a twelve-year chronic carriage infection. MBiol. 2013;4:e00388–13.PubMedGoogle Scholar
  21. O’Sullivan  BP, Torres  B, Conidi  G, Smole  S, Gauthier  C, Stauffer  KE, Burkholderia pseudomallei infection in a child with cystic fibrosis: acquisition in the Western Hemisphere. Chest. 2011;140:239–42. DOIPubMedGoogle Scholar
  22. Huis in ’t Veld  D, Wuthiekanun  V, Cheng  AC, Chierakul  W, Chaowagul  W, Brouwer  AE, The role and significance of sputum cultures in the diagnosis of melioidosis. Am J Trop Med Hyg. 2005;73:657–61 .PubMedGoogle Scholar
  23. Limmathurotsakul  D, Jamsen  K, Arayawichanont  A, Simpson  JA, White  LJ, Lee  SJ, Defining the true sensitivity of culture for the diagnosis of melioidosis using Bayesian latent class models. PLoS ONE. 2010;5:e12485. DOIPubMedGoogle Scholar
  24. Roesnita  B, Tay  ST, Puthucheary  SD, Sam  IC. Diagnostic use of Burkholderia pseudomallei selective media in a low prevalence setting. Trans R Soc Trop Med Hyg. 2012;106:131–3. DOIPubMedGoogle Scholar
  25. Glass  MB, Beesley  CA, Wilkins  PP, Hoffmaster  AR. Comparison of four selective media for the isolation of Burkholderia mallei and Burkholderia pseudomallei. Am J Trop Med Hyg. 2009;80:1023–8 .PubMedGoogle Scholar
  26. Wongsuvan  G, Limmathurotsakul  D, Wannapasni  S, Chierakul  W, Teerawattanasook  N, Wuthiekanun  V. Lack of correlation of Burkholderia pseudomallei quantities in blood, urine, sputum and pus. Southeast Asian J Trop Med Public Health. 2009;40:781–4 .PubMedGoogle Scholar
  27. Dance  DA, Wuthiekanun  V, Naigowit  P, White  NJ. Identification of Pseudomonas pseudomallei in clinical practice: use of simple screening tests and API 20NE. J Clin Pathol. 1989;42:645–8. DOIPubMedGoogle Scholar
  28. Tandhavanant  S, Wongsuvan  G, Wuthiekanun  V, Teerawattanasook  N, Day  NP, Limmathurotsakul  D, Monoclonal antibody-based immunofluorescence microscopy for the rapid identification of Burkholderia pseudomallei in clinical specimens. Am J Trop Med Hyg. 2013;89:165–8. DOIPubMedGoogle Scholar
  29. Inglis  TJ, Chiang  D, Lee  GS, Chor-Kiang  L. Potential misidentification of Burkholderia pseudomallei by API 20NE. Pathology. 1998;30:62–4. DOIPubMedGoogle Scholar
  30. Lowe  P, Engler  C, Norton  R. Comparison of automated and nonautomated systems for identification of Burkholderia pseudomallei. J Clin Microbiol. 2002;40:4625–7. DOIPubMedGoogle Scholar
  31. Inglis  TJ, Merritt  A, Chidlow  G, Aravena-Roman  M, Harnett  G. Comparison of diagnostic laboratory methods for identification of Burkholderia pseudomallei. J Clin Microbiol. 2005;43:2201–6. DOIPubMedGoogle Scholar
  32. Glass  MB, Popovic  T. Preliminary evaluation of the API 20NE and RapID NF plus systems for rapid identification of Burkholderia pseudomallei and B. mallei. J Clin Microbiol. 2005;43:479–83. DOIPubMedGoogle Scholar
  33. Amornchai  P, Chierakul  W, Wuthiekanun  V, Mahakhunkijcharoen  Y, Phetsouvanh  R, Currie  BJ, Accuracy of Burkholderia pseudomallei identification using the API 20NE system and a latex agglutination test. J Clin Microbiol. 2007;45:3774–6. DOIPubMedGoogle Scholar
  34. Koh  TH, Yong Ng  LS, Foon Ho  JL, Sng  LH, Wang  GC, Tzer Pin Lin  RV. Automated identification systems and Burkholderia pseudomallei. J Clin Microbiol. 2003;41:1809. DOIPubMedGoogle Scholar
  35. Weissert  C, Dollenmaier  G, Rafeiner  P, Riehm  J, Schultze  D. Burkholderia pseudomallei misidentified by automated system. Emerg Infect Dis. 2009;15:1799–801. DOIPubMedGoogle Scholar
  36. Lowe  P, Haswell  H, Lewis  K. Use of various common isolation media to evaluate the new VITEK 2 colorimetric GN card for identification of Burkholderia pseudomallei. J Clin Microbiol. 2006;44:854–6. DOIPubMedGoogle Scholar
  37. Zong  Z, Wang  X, Deng  Y, Zhou  T. Misidentification of Burkholderia pseudomallei as Burkholderia cepacia by the VITEK 2 system. J Med Microbiol. 2012;61:1483–4. DOIPubMedGoogle Scholar
  38. Podin  Y, Kaestli  M, McMahon  N, Hennessy  J, Ngian  HU, Wong  JS, Reliability of automated biochemical identification of Burkholderia pseudomallei is regionally dependent. J Clin Microbiol. 2013;51:3076–8. DOIPubMedGoogle Scholar
  39. Hodgson  K, Engler  C, Govan  B, Ketheesan  N, Norton  R. Comparison of routine bench and molecular diagnostic methods in identification of Burkholderia pseudomallei. J Clin Microbiol. 2009;47:1578–80. DOIPubMedGoogle Scholar
  40. Podin  Y, Sarovich  DS, Price  EP, Kaestli  M, Mayo  M, Hii  K, Burkholderia pseudomallei isolates from Sarawak, Malaysian Borneo, are predominantly susceptible to aminoglycosides and macrolides. Antimicrob Agents Chemother. 2014;58:162–6. DOIPubMedGoogle Scholar
  41. Anuntagool  N, Naigowit  P, Petkanchanapong  V, Aramsri  P, Panichakul  T, Sirisinha  S. Monoclonal antibody-based rapid identification of Burkholderia pseudomallei in blood culture fluid from patients with community-acquired septicaemia. J Med Microbiol. 2000;49:1075–8 .PubMedGoogle Scholar
  42. Dharakul  T, Songsivilai  S, Smithikarn  S, Thepthai  C, Leelaporn  A. Rapid identification of Burkholderia pseudomallei in blood cultures by latex agglutination using lipopolysaccharide-specific monoclonal antibody. Am J Trop Med Hyg. 1999;61:658–62 .PubMedGoogle Scholar
  43. Ekpo  P, Rungpanich  U, Pongsunk  S, Naigowit  P, Petkanchanapong  V. Use of protein-specific monoclonal antibody-based latex agglutination for rapid diagnosis of Burkholderia pseudomallei infection in patients with community-acquired septicemia. Clin Vaccine Immunol. 2007;14:811–2. DOIPubMedGoogle Scholar
  44. Kiratisin  P, Santanirand  P, Chantratita  N, Kaewdaeng  S. Accuracy of commercial systems for identification of Burkholderia pseudomallei versus Burkholderia cepacia. Diagn Microbiol Infect Dis. 2007;59:277–81 . DOIPubMedGoogle Scholar
  45. Lowe  W, March  JK, Bunnell  AJ, O’Neill  KL, Robison  RA. PCR-based methodologies used to detect and differentiate the Burkholderia pseudomallei complex: B. pseudomallei, B. mallei, and B. thailandensis. Curr Issues Mol Biol. 2013;16:23–54 .PubMedGoogle Scholar
  46. Price  EP, Dale  JL, Cook  JM, Sarovich  DS, Seymour  ML, Ginther  JL, Development and validation of Burkholderia pseudomallei–specific real-time PCR assays for clinical, environmental or forensic detection applications. PLoS ONE. 2012;7:e37723. DOIPubMedGoogle Scholar
  47. Novak  RT, Glass  MB, Gee  JE, Gal  D, Mayo  MJ, Currie  BJ, Development and evaluation of a real-time PCR assay targeting the type III secretion system of Burkholderia pseudomallei. J Clin Microbiol. 2006;44:85–90. DOIPubMedGoogle Scholar
  48. Morse  SA, Kellogg  RB, Perry  S, Meyer  RF, Bray  D, Nichelson  D, Detecting biothreat agents: the Laboratory Response Network. ASM News. 2003;69:433–7.
  49. Gee  JE, Sacchi  CT, Glass  MB, De  BK, Weyant  RS, Levett  PN, Use of 16S rRNA gene sequencing for rapid identification and differentiation of Burkholderia pseudomallei and B. mallei. J Clin Microbiol. 2003;41:4647–54 . DOIPubMedGoogle Scholar
  50. Clinical and Laboratory Standards Institute. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. CLSI document M45–A2. Wayne (PA): The Institute; 2010.
  51. Wuthiekanun  V, Cheng  AC, Chierakul  W, Amornchai  P, Limmathurotsakul  D, Chaowagul  W, Trimethoprim/sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei. J Antimicrob Chemother. 2005;55:1029–31. DOIPubMedGoogle Scholar
  52. Jenney  AW, Lum  G, Fisher  DA, Currie  BJ. Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis. Int J Antimicrob Agents. 2001;17:109–13. DOIPubMedGoogle Scholar
  53. Piliouras  P, Ulett  GC, Ashhurst-Smith  C, Hirst  RG, Norton  RE. A comparison of antibiotic susceptibility testing methods for cotrimoxazole with Burkholderia pseudomallei. Int J Antimicrob Agents. 2002;19:427–9. DOIPubMedGoogle Scholar
  54. Chantratita  N, Tandhavanant  S, Wongsuvan  G, Wuthiekanun  V, Teerawattanasook  N, Day  NP, Rapid detection of Burkholderia pseudomallei in blood cultures using a monoclonal antibody–based immunofluorescent assay. Am J Trop Med Hyg. 2013;89:971–2. DOIPubMedGoogle Scholar
  55. Wuthiekanun  V, Desakorn  V, Wongsuvan  G, Amornchai  P, Cheng  AC, Maharjan  B, Rapid immunofluorescence microscopy for diagnosis of melioidosis. Clin Diagn Lab Immunol. 2005;12:555–6 .PubMedGoogle Scholar
  56. Thibault  FM, Valade  E, Vidal  DR. Identification and discrimination of Burkholderia pseudomallei, B. mallei, and B. thailandensis by real-time PCR targeting type III secretion system genes. J Clin Microbiol. 2004;42:5871–4 . DOIPubMedGoogle Scholar
  57. Kaestli  M, Richardson  LJ, Colman  RE, Tuanyok  A, Price  EP, Bowers  JR, Comparison of TaqMan PCR assays for detection of the melioidosis agent Burkholderia pseudomallei in clinical specimens. J Clin Microbiol. 2012;50:2059–62. DOIPubMedGoogle Scholar
  58. Meumann  EM, Novak  RT, Gal  D, Kaestli  ME, Mayo  M, Hanson  JP, Clinical evaluation of a type III secretion system real-time PCR assay for diagnosing melioidosis. J Clin Microbiol. 2006;44:3028–30. DOIPubMedGoogle Scholar
  59. Chantratita  N, Meumann  E, Thanwisai  A, Limmathurotsakul  D, Wuthiekanun  V, Wannapasni  S, Loop-mediated isothermal amplification method targeting the TTS1 gene cluster for the detection of Burkholderia pseudomallei and diagnosis of melioidosis. J Clin Microbiol. 2008;46:568–73 . DOIPubMedGoogle Scholar
  60. Houghton  RL, Reed  DE, Hubbard  MA, Dillon  MJ, Chen  H, Currie  BJ, Development of a prototype lateral flow immunoassay (LFI) for the rapid diagnosis of melioidosis. PLoS Negl Trop Dis. 2014;8:e2727. DOIPubMedGoogle Scholar
  61. Sim  BM, Chantratita  N, Ooi  WF, Nandi  T, Tewhey  R, Wuthiekanun  V, Genomic acquisition of a capsular polysaccharide virulence cluster by non-pathogenic Burkholderia isolates. Genome Biol. 2010;11:R89. DOIPubMedGoogle Scholar
  62. Cheng  AC, O’Brien  M, Freeman  K, Lum  G, Currie  BJ. Indirect hemagglutination assay in patients with melioidosis in northern Australia. Am J Trop Med Hyg. 2006;74:330–4 .PubMedGoogle Scholar
  63. Cheng  AC, Peacock  SJ, Limmathurotsakul  D, Wongsuvan  G, Chierakul  W, Amornchai  P, Prospective evaluation of a rapid immunochromogenic cassette test for the diagnosis of melioidosis in northeast Thailand. Trans R Soc Trop Med Hyg. 2006;100:64–7. DOIPubMedGoogle Scholar
  64. Harris  PN, Ketheesan  N, Owens  L, Norton  RE. Clinical features that affect indirect-hemagglutination-assay responses to Burkholderia pseudomallei. Clin Vaccine Immunol. 2009;16:924–30. DOIPubMedGoogle Scholar
  65. Armstrong  PK, Anstey  NM, Kelly  PM, Currie  BJ, Martins  N, Dasari  P, Seroprevalence of Burkholderia pseudomallei in East Timorese refugees: implications for healthcare in East Timor. Southeast Asian J Trop Med Public Health. 2005;36:1496–502 .PubMedGoogle Scholar
  66. Clayton  AJ, Lisella  RS, Martin  DG. Melioidosis: a serological survey in military personnel. Mil Med. 1973;138:24–6 .PubMedGoogle Scholar
  67. Chantratita  N, Wuthiekanun  V, Thanwisai  A, Limmathurotsakul  D, Cheng  AC, Chierakul  W, Accuracy of enzyme-linked immunosorbent assay using crude and purified antigens for serodiagnosis of melioidosis. Clin Vaccine Immunol. 2007;14:110–3. DOIPubMedGoogle Scholar
  68. Limmathurotsakul  D, Chantratita  N, Teerawattanasook  N, Piriyagitpaiboon  K, Thanwisai  A, Wuthiekanun  V, Enzyme-linked immunosorbent assay for the diagnosis of melioidosis: better than we thought. Clin Infect Dis. 2011;52:1024–8. DOIPubMedGoogle Scholar
  69. Trikalinos  TA, Balion  CM. Chapter 9: options for summarizing medical test performance in the absence of a “gold standard.”. J Gen Intern Med. 2012;27(Suppl 1):S67–75. DOIPubMedGoogle Scholar
  70. Lim  C, Wannapinij  P, White  L, Day  NP, Cooper  BS, Peacock  SJ, Using a web-based application to define the accuracy of diagnostic tests when the gold standard is imperfect. PLoS ONE. 2013;8:e79489. DOIPubMedGoogle Scholar
  71. Karger  A, Stock  R, Ziller  M, Elschner  MC, Bettin  B, Melzer  F, Rapid identification of Burkholderia mallei and Burkholderia pseudomallei by intact cell matrix-assisted laser desorption/ionisation mass spectrometric typing. BMC Microbiol. 2012;12:229. DOIPubMedGoogle Scholar
  72. Weigel  LM, Sue  D, Michel  PA, Kitchel  B, Pillai  SP. A rapid antimicrobial susceptibility test for Bacillus anthracis. Antimicrob Agents Chemother. 2010;54:2793–800 . DOIPubMedGoogle Scholar
  73. Chetchotisakd  P, Chierakul  W, Chaowagul  W, Anunnatsiri  S, Phimda  K, Mootsikapun  P, Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial. Lancet. 2014;383:807–14 . DOIPubMedGoogle Scholar

Main Article

1Held September 14, 2013, in Bangkok, Thailand.

Page created: January 21, 2015
Page updated: January 21, 2015
Page reviewed: January 21, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external